RxDoctor Payments Data

Kaijun Huang, MD

Internal Medicine · Flushing, NYNPI 1043622814

Payments from drug & device makers

$2,416in general payments, 2019–2025

Across 98 payments — averaging $24.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$615
  • Lilly USA, LLC$408
  • Esperion Therapeutics, Inc.$169
  • Amgen$166
  • Amarin Pharma, Inc.$163
  • Gilead$125
  • plus $771 from 12 others

What the payments were for

  • Food & beverage$2,39699%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,416 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$53,061
Medicare patients
76
Services billed
772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl428$250,988
FarxigaDapagliflozin Propanediol241$249,863
JardianceEmpagliflozin78$89,113
OzempicSemaglutide64$70,101
RybelsusSemaglutide38$67,150
EliquisApixaban65$62,427
VemlidyTenofovir Alafenamide34$54,539
JanuviaSitagliptin Phosphate65$49,574
LinzessLinaclotide44$34,459
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$27,436
XareltoRivaroxaban25$27,409
MounjaroTirzepatide17$20,427
TrulicityDulaglutide17$16,698
TradjentaLinagliptin16$16,454
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$14,909

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$615$271,034277 claims
Novo NordiskOzempic, Rybelsus$62$137,251102 claims
Boehringer IngelheimJardiance, Tradjenta$105$105,56794 claims
PfizerEliquis, Abrysvo$25$71,43797 claims
GileadVemlidy$125$54,53934 claims
Lilly USA, LLCMounjaro, Trulicity$408$37,12534 claims
GSKTrelegy Ellipta, Shingrix$93$34,77284 claims
Johnson & JohnsonXarelto$88$27,40925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →